Besides, CD70 was found to be upregulated in refractory or recurrent tumors, including glioblastoma [40] and mantle cell lymphoma [41], More in-depth researchers found that other conditions, including but not limited to tissue injury, autoimmune statuses (e.g., inflammatory bowel disease), hypoxia, proinflammatory cytokines (TNF-α and IFN-γ), and CD40L-CD40 signaling, can promote CD70 expression [42–44]. This evidence concerns the gene CD40LG and glioblastoma.